Evidence map›Paper›PMID 39217267›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024

Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia.

Mark Slifstein, Wenchao Qu, Roberto Gil, Jodi J Weinstein, Greg Perlman, Thomas Jaworski-Calara, Jiayan Meng, Bao Hu, Scott J Moeller, Guillermo Horga and 1 more

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Kappa opioid receptor control of motivated behavior revisited.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mark SlifsteinRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA. mark.slifstein@stonybrookmedicine.edu.
Wenchao QuRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Roberto GilRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Jodi J WeinsteinRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.ORCID http://orcid.org/0000-0002-0396-3596
Greg PerlmanRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.ORCID http://orcid.org/0000-0001-9992-4278
Thomas Jaworski-CalaraRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Jiayan MengRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Bao HuRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
Scott J MoellerRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.ORCID http://orcid.org/0000-0002-4449-0844
Guillermo HorgaVagelos College of Physicians and Surgeons, Columbia University, Stony Brook, New York, USA.
Anissa Abi-DarghamRenaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.

Funding

Towards an Integrated Understanding of Neurotransmitter Dysfunction in Schizophrenia: a Multimodal MRI StudyK23MH115291 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI WEINSTEIN, JODI JAY · 2018 to 2024
$1.2M
Functional MRI in SchizophreniaR21MH126260 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DAI, WEIYING, HE, XIANG · 2022 to 2023
$467k
Preliminary imaging studies of the kappa opioid receptors in schizophrenia and their relationship to dopamine functionR21MH125454 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI ABI-DARGHAM, ANISSA · 2021 to 2022
$439k
NIMH NIH HHS K23 MH115291NIMH NIH HHS R21 MH125454NIMH NIH HHS R21 MH126260U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) 5R21MH125454U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) 5R21MH125454-0U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) 5R21MH125454-02
6 · The paper itself

Abstract

The kappa opioid receptor (KOR) and its endogenous agonist dynorphin have been implicated in multiple psychiatric conditions including psychotic disorders. We tested the hypotheses that kappa expression is elevated and associated with psychotic symptoms in schizophrenia. We measured kappa expression in unmedicated patients with schizophrenia (7 female, 6 male) and matched controls (7 female, 6 male) with positron emission tomography (PET). We also acquired a measurement of cumulative dopamine activity over the life span in the same subjects using neuromelanin sensitive MRI. We hypothesized that neuromelanin accumulation would be higher in patients than controls and that in patients there would be a positive association between KOR availability and neuromelanin accumulation. Fourteen patients and thirteen controls were enrolled. Whole brain dynamic PET imaging data using the KOR selective tracer [

Indexed as

AnhedoniaMagnetic Resonance ImagingPositron-Emission TomographyReceptors, Opioid, kappaSchizophreniaAdultBrainFemaleHumansMaleMelaninsMiddle AgedYoung AdultMelaninsneuromelaninReceptors, Opioid, kappa

Identifiers

PMID39217267
PMCPMC11480413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.